Glaucoma Clinical Trial
Official title:
Ahmed Glaucoma Valve Implantation; Graft-Free Short Tunnel Small Flap Versus Scleral Patch Graft
Glaucoma implants have been used for refractory glaucoma and are gaining popularity as a
primary procedure in selected patients. In order to prevent tube erosion, a biologic material
such as pericardium, cornea, and sclera is used as coverage over the tube. Despite this
preventive measures, patch graft thinning and silicon tube exposure are still a serious
complications and may occur in 1%-7% of eyes after glaucoma implantation. In this study we
used a novel technique named short tunnel small flap (STSF) by tunneling the sclera without
using any biological material . efficacy and safety of this technique is comparing with
conventional scleral patch graft.
This randomized clinical trial, was performed at the Glaucoma Clinic of Labbafinejad Medical
Center, Tehran, IRAN from September 2015 to January 2017 . The study was approved by the
ethics committee at the Ophthalmic Research Center, Shahid Beheshti University of Medical
Sciences, Tehran, Iran and followed the tenets of the Declaration of Helsinki. After
explaining all therapeutic options and their side effects, the written consent form was
obtained from all patient. 80 eyes of 80 patients with refractory glaucoma underwent AGV
implantation by short tunnel small flap technique (group1) or scleral patch graft (group2)
randomly. Primary outcome measure is Intraocular pressure(IOP) and Tube exposure, and
secondary outcome measure is success rate that is defined as intraocular pressure (IOP) > 5
mmHg, ≤ 21 mmHg, and IOP reduction ≥ 20% from baseline at two consecutive visits after three
months, no reoperation for glaucoma. Outcome measures are compared at 1, 3 , 6 and 12 months
postoperatively.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06000865 -
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
|
N/A | |
Recruiting |
NCT06278597 -
Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03274024 -
The Asia Primary Tube Versus Trab (TVT) Study
|
N/A | |
Completed |
NCT04552964 -
Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma
|
N/A | |
Recruiting |
NCT01957267 -
Functional and Structural Imaging for Glaucoma
|
||
Active, not recruiting |
NCT04624698 -
iStent Inject New Enrollment Post-Approval Study
|
N/A | |
Completed |
NCT04020705 -
The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma
|
N/A | |
Completed |
NCT03150160 -
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
|
Phase 4 | |
Not yet recruiting |
NCT05581498 -
Glaucoma Exercise as Medicine Study (GEMS).
|
N/A | |
Recruiting |
NCT02921568 -
Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes
|
N/A | |
Active, not recruiting |
NCT02901730 -
Clinical Study of LPI With Different Laser Wavelengths
|
N/A | |
Completed |
NCT02955849 -
A Trial of China Laser and Surgery Study Glaucoma in Rural China
|
Early Phase 1 | |
Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
Recruiting |
NCT02554214 -
Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
|
N/A | |
Active, not recruiting |
NCT02390284 -
Stop Retinal Ganglion Cell Dysfunction Study
|
Phase 3 | |
Completed |
NCT02653963 -
Triamcinolone for Ahmed Glaucoma Valve
|
N/A | |
Completed |
NCT02520674 -
Glaucoma Screening With Smartphone Ophthalmology
|
N/A | |
Completed |
NCT02628223 -
180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
|
N/A | |
Completed |
NCT02246764 -
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 |